AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12137177 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9820296 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (8 million IU every other day subcutaneously)
Number of subjects: 718
Study 9820296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study 9820296 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 718
Study 7626346 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase 1.5 million units over 30 min (n = 57)
Number of subjects: 112
Study 7626346 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 55)
Number of subjects: 112
Study 7626346 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 112
Study 7626346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 7626346 — intervention group
Group type: EXPERIMENTAL
Intervention: ST depression ≥ 3 mm
Number of subjects: 112
Study 7626346 — intervention group
Group type: EXPERIMENTAL
Intervention: ST depression ≥ 2 mm
Number of subjects: 112
Study 2466846 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III and low-dose heparin
Number of subjects: 83
Study 2466846 — intervention group
Group type: COMPARATOR
Intervention: Dextran 40
Number of subjects: 83
Study 2466846 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III and low-dose heparin (in cemented prosthesis group)
Number of subjects: 83
Study 2466846 — intervention group
Group type: COMPARATOR
Intervention: Dextran 40 (in cemented prosthesis group)
Number of subjects: 83
Study 2466846 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Number of subjects: 83
Study 404763 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 96
Study 404763 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 96
Study 31682462 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 196
Study 31682462 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 196
Study 29747140 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 32
Study 29747140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29747140 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram group
Number of subjects: 32
Study 25796036 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 20
Study 25796036 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock music
Number of subjects: 20
Study 25796036 — intervention group
Group type: COMPARATOR
Intervention: No music (sham procedure)
Number of subjects: 20
Study 23907610 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instruments
Number of subjects: 100
Study 23907610 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 100
Study 20203546 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 66
Study 20203546 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 1.5 mg/kg and esmolol 1.0 mg/kg
Number of subjects: 66
Study 18986416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler echocardiography
Number of subjects: 32
Study 18986416 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial performance index (MPI)
Number of subjects: 32
Study 16075981 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Number of subjects: 0
Study 16075981 — intervention group
Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 0
Study 16075981 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Montelukast sodium and Loratadine
Number of subjects: 0
Study 11960947 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1,500 mg/day)
Number of subjects: 28
Study 11960947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9534832 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily) for 1 week
Number of subjects: 0
Study 9534832 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily) for 3 weeks
Number of subjects: 0
Study 9534832 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily) for 8 weeks in depressed patients
Number of subjects: 0
Study 7892447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cine phase-contrast with respiratory compensation (CPC-R)
Number of subjects: 14
Study 7892447 — intervention group
Group type: COMPARATOR
Intervention: Cine phase-contrast without respiratory compensation (CPC)
Number of subjects: 14
Study 7892447 — intervention group
Group type: COMPARATOR
Intervention: Phase-contrast with two signals acquired (PC-2)
Number of subjects: 14
Study 7892447 — intervention group
Group type: COMPARATOR
Intervention: Phase-contrast with eight signals acquired (PC-8)
Number of subjects: 14
Study 2795761 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial cell seeded grafts at a density of 3500 cells/cm2
Number of subjects: 23
Study 2795761 — intervention group
Group type: COMPARATOR
Intervention: Sham seeded grafts with culture medium
Number of subjects: 23
Study 202906 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyc chemotherapy, high-dosage vitamin-A treatment, Endoxan, immunotherapy, and proteolytic enzymes in 5 combinations of therapy
Number of subjects: 56
Study 30998816 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hearing aid use
Number of subjects: 1898
Study 30998816 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorer measured hearing
Number of subjects: 1898
Study 30998816 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Hearing Handicap Inventory-Screening scores
Number of subjects: 1898
Study 30998816 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to health insurance coverage
Number of subjects: 1898
Study 30998816 — intervention group
Group type: EXPERIMENTAL
Intervention: Place of residence
Number of subjects: 1898
Study 28329240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-enriched air (FiO2 0.50, hyperoxia)
Number of subjects: 22
Study 28329240 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (FiO2 0.21, normoxia)
Number of subjects: 22
Study 26086082 — intervention group
Group type: EXPERIMENTAL
Intervention: Game On: Know Alcohol (GOKA) intervention, a school-based alcohol social marketing program
Number of subjects: 2114
Study 23228249 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 125
Study 23228249 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 125
Study 22124642 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional lower blepharoplasty and routine lateral canthopexy
Number of subjects: 50
Study 22124642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blepharoplasty with fat bags transposition and routine lateral canthopexy
Number of subjects: 50
Study 19567927 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived caffeine condition
Number of subjects: 15
Study 19567927 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 15
Study 19567927 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived placebo condition
Number of subjects: 15
Study 19567927 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 15
Study 16948122 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative interferon‐α therapy (Group 1)
Number of subjects: 155
Study 16948122 — intervention group
Group type: COMPARATOR
Intervention: No postoperative interferon‐α therapy (Group 2)
Number of subjects: 155
Study 15019657 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free immunosuppressive regimen (mycophenolate mofetil (MMF) and sirolimus (Sir))
Number of subjects: 30
Study 15019657 — intervention group
Group type: COMPARATOR
Intervention: CNI-based immunosuppression (control group)
Number of subjects: 30
Study 11318053 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning Stimulus (WS) followed by Imperative Stimulus (IS)
Number of subjects: 0
Study 11318053 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintentional contributions to nonspecific preparation
Number of subjects: 0
Study 9135342 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5% bupivacaine
Number of subjects: 40
Study 9135342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine)
Number of subjects: 40
Study 9135342 — intervention group
Group type: COMPARATOR
Intervention: Both groups (bupivacaine and control)
Number of subjects: 40
Study 7931470 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etoposide and cisplatin (EP)
Number of subjects: 90
Study 7931470 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose etoposide and cisplatin (EP)
Number of subjects: 90
Study 7931470 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized standard-dose therapy
Number of subjects: 90
Study 2902738 — intervention group
Group type: EXPERIMENTAL
Intervention: CQP 201-403 (0.01 mg)
Number of subjects: 24
Study 2902738 — intervention group
Group type: EXPERIMENTAL
Intervention: CQP 201-403 (0.02 mg)
Number of subjects: 24
Study 2902738 — intervention group
Group type: EXPERIMENTAL
Intervention: CQP 201-403 (0.03 mg)
Number of subjects: 24
Study 2902738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29778586 — intervention group
Group type: EXPERIMENTAL
Intervention: Two visits at 3 and 6 weeks postpartum (intervention)
Number of subjects: 200
Study 29778586 — intervention group
Group type: COMPARATOR
Intervention: Routine care with a single 6-week postpartum visit (control)
Number of subjects: 200
Study 30645844 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Huaju Recipe (YHR) + routine Western drugs
Number of subjects: 96
Study 30645844 — intervention group
Group type: COMPARATOR
Intervention: placebo + routine Western drugs
Number of subjects: 96
Study 26603252 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron pyrophosphate (approximately 1 mg/kg) daily until 9 months of age
Number of subjects: 0
Study 26603252 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily until 9 months of age
Number of subjects: 0
Study 23562680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter food consumption (variety of items consumed, unweighted score)
Number of subjects: 2327
Study 23562680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitterness-weighted score
Number of subjects: 2327
Study 23562680 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 2327
Study 20946752 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard individual cognitive behavioral therapy (CBT) for alcohol use disorders
Number of subjects: 158
Study 20946752 — intervention group
Group type: COMPARATOR
Intervention: Female-specific CBT for alcohol use disorders
Number of subjects: 158
Study 20946752 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol behavioral couple therapy
Number of subjects: 158
Study 20946752 — intervention group
Group type: COMPARATOR
Intervention: Blended individual CBT and alcohol behavioral couple therapy
Number of subjects: 158
Study 18093797 — intervention group
Group type: EXPERIMENTAL
Intervention: Weigl‐R (modified version of the Weigl Color Form Sorting Test)
Number of subjects: 85
Study 18093797 — intervention group
Group type: EXPERIMENTAL
Intervention: Weigl‐R
Number of subjects: 85
Study 15246968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg oral solution of GI181771X
Number of subjects: 61
Study 15246968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg oral solution of GI181771X
Number of subjects: 61
Study 15246968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg oral solution of GI181771X
Number of subjects: 61
Study 15246968 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg tablet of GI181771X
Number of subjects: 61
Study 15246968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11167667 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (thrombin inhibitor) administered intravenously; specific dosage and duration not mentioned.
Number of subjects: 1026
Study 9626201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg intravenously every 3 to 4 weeks)
Number of subjects: 382
Study 9626201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously every 3 to 4 weeks)
Number of subjects: 382
Study 7881452 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic plus caffeine (C)
Number of subjects: 0
Study 7881452 — intervention group
Group type: COMPARATOR
Intervention: Analgesic alone (A)
Number of subjects: 0
Study 7881452 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 3295599 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg b.i.d. by IV route)
Number of subjects: 184
Study 3295599 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (5000 I.U. t.i.d. s.c.)
Number of subjects: 184
Study 3295599 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 184
Study 3295599 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 184
Study 3295599 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide and Calcium heparin
Number of subjects: 184
Study 31647010 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPETUS-D intervention
Number of subjects: 24
Study 31647010 — intervention group
Group type: COMPARATOR
Intervention: Usual training opportunities (control)
Number of subjects: 24
Study 30070110 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalytic Janus colloids with controlled rotary motion and gravity influence
Number of subjects: 0
Study 30070110 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalytic Janus colloids interacting with topographical features
Number of subjects: 0
Study 30070110 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical gradients influencing catalytic Janus colloids
Number of subjects: 0
Study 30070110 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex interactions in catalytic Janus colloids
Number of subjects: 0
Study 26739683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg twice daily)
Number of subjects: 0
Study 26739683 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg three times daily)
Number of subjects: 0
Study 26739683 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg once daily)
Number of subjects: 0
Study 25274713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention (computer-based, 2 days a week for 60 min over 10 weeks)
Number of subjects: 45
Study 25274713 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 25274713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 45
Study 22273843 — intervention group
Group type: EXPERIMENTAL
Intervention: NOURISH intervention targeting parents of overweight children
Number of subjects: 0
Study 22273843 — intervention group
Group type: COMPARATOR
Intervention: Control group (parents not participating in NOURISH)
Number of subjects: 0
Study 22273843 — intervention group
Group type: EXPERIMENTAL
Intervention: NOURISH intervention
Number of subjects: 0
Study 22273843 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20351157 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated paging system for critical values
Number of subjects: 108
Study 20351157 — intervention group
Group type: COMPARATOR
Intervention: Usual care (telephone call to the patient's ward)
Number of subjects: 108
Study 17394642 — intervention group
Group type: EXPERIMENTAL
Intervention: TSP 0.5%
Number of subjects: 30
Study 17394642 — intervention group
Group type: EXPERIMENTAL
Intervention: TSP 1%
Number of subjects: 30
Study 17394642 — intervention group
Group type: COMPARATOR
Intervention: HA 0.2%
Number of subjects: 30
Study 15672850 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood culture
Number of subjects: 507
Study 15672850 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum culture
Number of subjects: 507
Study 15672850 — intervention group
Group type: EXPERIMENTAL
Intervention: Serology (acute and convalescent serum samples)
Number of subjects: 507
Study 15672850 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall etiological diagnosis
Number of subjects: 507
Study 15672850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen identification
Number of subjects: 507
Study 11713061 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 607
Study 11713061 — intervention group
Group type: COMPARATOR
Intervention: Surgery (trabeculectomy with or without 5-fluorouracil)
Number of subjects: 607
Study 11713061 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 607
Study 9165323 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of full fat milk
Number of subjects: 48
Study 9165323 — intervention group
Group type: COMPARATOR
Intervention: 200 ml of still mineral water
Number of subjects: 48
Study 7956714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (300 mg/day)
Number of subjects: 27
Study 7956714 — intervention group
Group type: COMPARATOR
Intervention: Control (AS-negative group)
Number of subjects: 27
Study 3658570 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (30 mg/kg/d)
Number of subjects: 8
Study 3658570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3658570 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine
Number of subjects: 8
Study 31725085 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct lateral (DL) starting point
Number of subjects: 48
Study 31725085 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral (PL) starting point
Number of subjects: 48
Study 31725085 — intervention group
Group type: EXPERIMENTAL
Intervention: SNVB width
Number of subjects: 48
Study 31725085 — intervention group
Group type: EXPERIMENTAL
Intervention: DL 30-degree group
Number of subjects: 48
Study 31725085 — intervention group
Group type: EXPERIMENTAL
Intervention: PL 0-degree group
Number of subjects: 48
Study 31112429 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring OUD and CUD
Number of subjects: 234181
Study 31112429 — intervention group
Group type: COMPARATOR
Intervention: OUD only
Number of subjects: 234181
Study 27993298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 273
Study 27993298 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 273
Study 25287712 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA individuals
Number of subjects: 39
Study 25287712 — intervention group
Group type: COMPARATOR
Intervention: AGA individuals
Number of subjects: 39
Study 23601143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics therapy (IVAT) for exacerbation, duration: 14 days.
Number of subjects: 20
Study 23601143 — intervention group
Group type: COMPARATOR
Intervention: Control group (stable patients), N=10.
Number of subjects: 20
Study 23601143 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity monitored during IVAT using a SenseWear armband.
Number of subjects: 20
Study 21397957 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy and tympanostomy tubes
Number of subjects: 87
Study 21397957 — intervention group
Group type: COMPARATOR
Intervention: Adenoidectomy alone
Number of subjects: 87
Study 19325192 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil treatment
Number of subjects: 1337
Study 16340944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (1.9 g/kg BW)
Number of subjects: 15
Study 16340944 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (1.3 g/kg BW)
Number of subjects: 15
Study 15037537 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg/d)
Number of subjects: 70
Study 15037537 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (50 mg/d)
Number of subjects: 70
Study 11130772 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (C), 2.5 mg once daily
Number of subjects: 54
Study 11130772 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (C)
Number of subjects: 54
Study 11130772 — intervention group
Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 54
Study 9045468 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/INF-alpha
Number of subjects: 23
Study 9045468 — intervention group
Group type: COMPARATOR
Intervention: 5-FU +/- leucovorin
Number of subjects: 23
Study 8286176 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy
Number of subjects: 0
Study 8286176 — intervention group
Group type: COMPARATOR
Intervention: Open Cholecystectomy
Number of subjects: 0
Study 31166550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation (IMF) for six weeks after mandibular setback surgery
Number of subjects: 36
Study 29330312 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 807
Study 29330312 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 807
Study 29330312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel plus aspirin)
Number of subjects: 807
Study 29330312 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy (aspirin)
Number of subjects: 807
Study 26916697 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 16
Study 26916697 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16
Study 24743864 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia (n = 258)
Number of subjects: 258
Study 24743864 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with persecutory delusions (n = 142)
Number of subjects: 258
Study 24743864 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalizing subgroup (n = 70)
Number of subjects: 258
Study 24743864 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-blaming subgroup (n = 188)
Number of subjects: 258
Study 24743864 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 51)
Number of subjects: 258
Study 22472744 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 275